



Attorney Docket No. 25352-0003P8

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the US Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington DC 20231, on January 11, 2002.

Derek P. Freyberg
Derek P. Freyberg, Reg. No. 29,250

1/11/02
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Lawrence M. Kauvar, et al. : Confirmation No.: 8907

App. No.: 09/903,442 : Art Unit: 1615

Filed: July 10, 2001 : Examiner: Not yet known

For: THERAPEUTIC COMPOSITIONS CONTAINING GLUTATHIONE ANALOGS

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant directs the attention of the Office to the documents listed on the attached Form PTO-1449 substitute (1 sheets), which may be relevant to the examination of this application.

Also included is an International Search Report for a PCT application corresponding to this application. The documents listed on the Form PTO-1449 as 1, 2, and 4-6 are in order (within category) of the International Search Report, with the non-ISR document listed below them.

The Examiner is requested to initial and return a copy of the form with future communications relating to this application.

RECEIVED
JAN 30 2002
PATENTS
TECH CENTER 1600/2900
6P/1615
2



TECH CENTER 1600/2900

JAN 30 2002

RECEIVED

No representation is made by this Information Disclosure Statement that a search has been made; or that the information disclosed is, or is considered to be, material to patentability under 37 CFR 1.56(b).

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Derek P. Freyberg".

Derek P. Freyberg
Attorney for Applicant
Reg. No. 29,250

Customer No.: 25213


Heller Ehrman White & McAuliffe LLP
275 Middlefield Road
Menlo Park, California 94025-3506
(650) 324-7014

Dated: January 11, 2002

INFORMATION DISCLOSURE STATEMENT

(37 CFR 1.56, 1.97, and 1.98)

SHEET 1 OF 1



ATTORNEY DOCKET

25352-0003P8

APPLICATION NO.

09/903442

APPLICANT(S)

Lawrence M. Kauvar et al.

FILING DATE

July 10, 2001

GROUP

16082900

RECEIVED
JAN 30 2002
TECH CENTER 16082900**U.S. PATENT DOCUMENTS**

† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)

FOREIGN PATENT DOCUMENTS

† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY	TRANSLATION (YES/NO)
	1	96/40205	12/1996	WO	
	2	95/08563	03/1995	WO	
	3	1 072 608 A1	01/2001	EP	

OTHER DOCUMENTS

† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
	4	Ciaccio P. J. et al, "Modulation of Detoxification Gene Expression In Human Colon HT29 Cells by Glutathione-S-Transferase Inhibitors", Molecular Pharmacology, Vol. 48, No. 4, October 1, 1995, pp. 639-647.
	5	Morgan A. S. et al., "Isozyme-Specific Glutathione S-Transferase Inhibitors Potentiate Drug Sensitivity in Cultured Human Tumor Cell Lines", Cancer Chemotherapy and Pharmacology, Vol. 37, No. 4, 1996, pp. 363-370.
	6	Schultz M et al., "Inhibitors Of Glutathione S-Transferases As Therapeutic Agents", Advanced Drug Delivery Reviews, Vol. 26, No. 2/03, July 1, 1997, pp. 91-104.

EXAMINER'S SIGNATURE

DATE CONSIDERED

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. *Include copy of this form in next communication to applicant.*

* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).